- Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Olema Pharmaceuticals Inc Palazestrant Phase 2 Monotherapy Clinical Update Presentation TranscriptOct 23, 2023
- Olema Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Olema Pharmaceuticals Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Olema Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Olema Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Olema Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 23, 2023
- Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Olema Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Olema Pharmaceuticals Inc at Jefferies London Healthcare Conference TranscriptNov 16, 2022
- Olema Pharmaceuticals Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- Olema Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Olema Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) TranscriptApr 14, 2022
- Olema Pharmaceuticals Inc to Review the Phase 1 Clinical Data for OP-1250 TranscriptNov 30, 2021
- Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
Olema Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Welcome to another great afternoon session here at the Jefferies Healthcare Conference. I'm pleased to have with us the CEO of Olema Pharmaceuticals, Sean Bohen, up here with us. Sean, Olema is developing an oral CERAN. If you'd like to get a little more tactical, we'll get into that.
Questions & Answers
But importantly, there's been a lot of developments data recently and upcoming data later this year. So let's talk a little bit about, just from a high level, first is introduction. What -- where are we with OP-1250 today? What do we know about this molecule today?
What do we know about it recently with some recent data that's presented? And what do you think the street is not appreciating about this molecule you have for breast cancer?
Yes, great. Well, with two hours, we'll be sure to be able to cover all of that. Yeah, no.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)